Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

SAMe Is Effective In Preventing Formation Of Primary Liver Cancer In Rats
A new study investigated the effectiveness of S-adenosylmethionine (SAMe) in the prevention and treatment of hepatocellular carcinoma (HCC) or primary liver cancer. SAMe, a widely available nutritional supplement, with little known side effects, was found to be effective in preventing the formation of HCC in rats. However, high enough levels of SAMe were not attainable to successfully treat established HCC. The findings are available in the August issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases.

Accouncing The Leading European Congress On Cardiac Arrhythmias And Pacing: EUROPACE 2009
EUROPACE, the official congress of the European Heart Rhythm Association (EHRA), is the foremost European meeting on cardiac arrhythmias and pacing. More than 4,000 participants are expected to attend this year"s event, whose main themes are atrial fibrillation and sudden cardiac death.
News of the day
Debate Continues On Administration Of Magnesium Sulfate To Pregnant Women To Prevent Cerebral Palsy In Pre-Term Infants
Cerebral palsy (CP) is the most prevalent chronic childhood motor disability with an estimated lifetime cost of nearly $1 million per individual. There is evidence that magnesium sulfate (MgSO4) can reduce the incidence of CP for very early preterm infants. Many thousands of pregnant women and their fetuses are exposed to MgSO4 every year in the United States for a variety of indications, and most obstetricians are comfortable with its use. Yet, there is still some controversy over whether magnesium sulfate is truly protective against CP. In three articles published in the June 2009 issue of theAmerican Journal of Obstetrics & Gynecology, the authors shed some light on the debate.
Medical Devices

Bosentan Is Cost-Effective For Patients With Moderate PAH

Bosentan appears to be a more cost-effective initial treatment option for patients with moderate pulmonary arterial hypertension (PAH), classified as WHO functional class III, than no active intervention. A cost-utility model was constructed to evaluate the cost-effectiveness of bosentan compared with no active intervention, both added to palliative care in the UK. In the model, simulated patients remained on their initial intervention until death or until they deteriorated to functional class IV, which triggered initiation of intravenous epoprostenol treatment. In the base-case analysis, which assumed that first line treatment did not affect survival, bosentan was more effective and less costly than no active intervention. When survival benefits associated with bosentan treatment were taken into consideration, bosentan was found to be a potential cost effective first line treatment. The work, led by Matt Stevenson was conducted at the University of Sheffield. Dr Stevenson commented: "Long-term follow-up data from randomised controlled trials show that bosentan significantly delays progression to more severe states compared with no active intervention. This results in both potential cost-savings due to a reduction in the duration of relatively expensive epoprostenol treatment and in an improvement in the quality of life for patients." This study is published in Value in Health, the official journal of the International Society for Pharmacoeconomics and Outcomes Research. Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research and help health care leaders to make decisions that are solidly evidence-based. The journal is published bi-monthly and has a regular readership of over 4,000 clinicians, decision-makers, and researchers worldwide. ISPOR is a nonprofit, international organization that strives to translate pharmacoeconomics and outcomes research into practice to ensure that society allocates scarce health care res wisely, fairly, and efficiently. ISPOR


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009